INSPECS Group Full Year 2024 Earnings: UK£0.045 loss per share (vs UK£0.01 loss in FY 2023)

INSPECS Group (LON:SPEC) Full Year 2024 Results

Key Financial Results

• Revenue: UK£198.3m (down 2.5% from FY 2023).
• Net loss: UK£4.61m (loss widened by 362% from FY 2023).
• UK£0.045 loss per share (further deteriorated from UK£0.01 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

INSPECS Group Earnings Insights

Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's shares are down 6.0% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for INSPECS Group that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.